What is the recommended treatment and dosage of Fosfomycin for urinary tract infections (UTIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fosfomycin for Urinary Tract Infections

Direct Recommendation

For uncomplicated cystitis in women, use a single 3-gram oral dose of fosfomycin tromethamine; for complicated UTIs, fosfomycin is NOT recommended as first-line therapy, but may be considered as salvage therapy using 3 grams orally every 48-72 hours for 3 total doses when other agents have failed. 1, 2


Uncomplicated Cystitis (First-Line Use)

Standard Dosing

  • Single 3-gram oral dose is the FDA-approved regimen for uncomplicated UTI (acute cystitis) in women 18 years and older 2
  • Mix the granules with water before ingesting; never take in dry form 2
  • May be taken with or without food 2
  • Provides therapeutic urinary concentrations for 24-48 hours 1, 3

Guideline Support

  • The American Urological Association recommends fosfomycin as one of three first-line therapies for uncomplicated UTIs (Grade B evidence) 3
  • The European Association of Urology lists fosfomycin as a first-line option, with comparable clinical efficacy to nitrofurantoin but with single-dose convenience 3
  • Clinical and bacteriological cure rates of 75-90% at 5-11 days post-therapy, with 62-93% eradication at 4-6 weeks 4

Key Advantages

  • Single-dose regimen improves adherence compared to 3-7 day courses 3
  • Minimal collateral damage to intestinal flora 3
  • Safe in pregnancy for asymptomatic bacteriuria 3
  • Effective against multidrug-resistant pathogens including ESBL-producing organisms and VRE 3, 5

Complicated UTIs (Restricted Use)

Critical Restrictions

The American College of Physicians and European Association of Urology explicitly state that fosfomycin is NOT recommended for complicated UTIs or pyelonephritis due to insufficient efficacy data. 1, 6

When to Avoid Single-Dose Fosfomycin

  • Never use for pyelonephritis - insufficient efficacy data 1, 3
  • Not first-line for complicated UTIs - single-dose achieves therapeutic concentrations for only 24-48 hours, which is inadequate 1
  • Not recommended for men with UTIs - limited clinical efficacy data in this population 3
  • Do not use for non-fermenting gram-negative rods (e.g., Pseudomonas) - lacks sufficient data and has poor efficacy 6

Salvage Therapy Exception (Off-Label)

The Infectious Diseases Society of America suggests considering a multi-dose regimen for complicated lower UTIs when first-line agents have failed: 1

  • Dosing: 3 grams orally every 48-72 hours for a total of 3 doses
  • Indications: Previous treatment failure, multidrug-resistant pathogens, or intolerance to first-line agents 7
  • Evidence quality: Lower-quality evidence; this is a weak recommendation 1

Intravenous Fosfomycin for Complicated Upper UTI

  • Dosing: 6 grams IV every 8 hours for 7 days (14 days if concurrent bacteremia) 1, 7
  • Based on the ZEUS trial showing superiority over piperacillin-tazobactam for complicated upper UTIs 1, 7
  • Particularly effective against ESBL-producing organisms, carbapenem-resistant Enterobacterales, and MDR gram-negatives 7
  • Limitation: Not widely available in many countries 1

Special Populations and Pathogens

Multidrug-Resistant Organisms

  • ESBL-producing E. coli: 96% susceptibility rate; fosfomycin is the most reliable oral option after carbapenems 5
  • Vancomycin-resistant Enterococcus (VRE): 81% susceptibility; single 3-gram dose for uncomplicated UTI 3, 5
  • Carbapenem-resistant Enterobacterales: May consider fosfomycin, though specific dosing for complicated UTI not established 1

Pregnancy

  • Safe for use in pregnancy 3
  • Recommended for asymptomatic bacteriuria in pregnant women as standard short-course or single-dose treatment 3

Men

  • Not recommended for routine use due to limited clinical efficacy data 3

Monitoring and Follow-Up

When to Reassess

  • If symptoms do not resolve by end of treatment or recur within 2 weeks, obtain urine culture and antimicrobial susceptibility testing 1, 3
  • Routine post-treatment cultures are NOT indicated for asymptomatic patients 3

Adverse Effects

  • Most common: diarrhea, nausea, and vomiting - generally mild and self-limiting 1, 4
  • Transient gastrointestinal symptoms occur but are well-tolerated 4

Guideline-Recommended Alternatives for Complicated UTI

When fosfomycin is inappropriate for complicated UTI, the Infectious Diseases Society of America strongly recommends: 1

  • Ceftazidime-avibactam
  • Meropenem-vaborbactam
  • Aminoglycosides (moderate-certainty evidence, though nephrotoxicity risk increases after 7 days) 6
  • Carbapenems for susceptible isolates 6

Critical Pitfalls Summary

  1. Never use single-dose oral fosfomycin for pyelonephritis - inadequate duration of therapeutic concentrations 1
  2. Do not use as first-line for complicated UTIs - reserve for salvage therapy only 1
  3. Avoid in non-fermenting organisms (Pseudomonas, Acinetobacter) - poor efficacy 6
  4. Do not routinely use in men - insufficient efficacy data 3
  5. Do not treat asymptomatic bacteriuria except in pregnant women or before urological procedures 3

References

Guideline

Fosfomycin for Complicated UTI: Treatment Course

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fosfomycin Treatment for Uncomplicated Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fosfomycin for UTI with Non-Fermenting Gram-Negative Rods

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.